Partner With Us NRI

Dr Reddys Laboratories Ltd share Price

Company details

6M Return 24.84%
1Y Return 32.85%
Mkt Cap.(Cr) 91,889.78
Volume 489,557
Div Yield 0.72%
OI Chg %
Volume 489,557

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
In line numbers boosted by gRevlimid, divestitures of brands…

    Dr Reddy’s (DRL) portfolio includes pharmaceutical generics, APIs, custom pharmaceutical services, biosimilar and complex formulations. •Revenue breakup: US (37%), India (18%), Russia and CIS (12%), Europe (8%), RoW (6%) and API (17%) •It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe


    Reported steady set of numbers despite Covid revenue vaccum this Quarter, in line with our estimates.

    • Sales were up 8% YoY to ₹ 5338.3 crore
    • EBITDA was at ₹ 1215.7 crore, up 125.4% YoY with margins at 22.8% [Note: Base of Q3FY21 had ₹ 597.2 crore impairment cost].
    • Adjusted PAT was steady YoY at ₹ 695.8 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Dr. Reddy's Laboratories announced Q1FY24 results:

  • Revenues of Rs 67,384 million, Up 29% YoY; Up 7% QoQ
  • Gross margin of 58.7% (Q1FY23: 49.9%; Q4FY23: 57.2%)
  • SG&A expenses of Rs 17,702 million (Up 14% YoY; Down 2% QoQ)
  • R&D expenses of Rs 4,984 million (7.4% of Revenues)
  • EBITDA of Rs 21,372 million (31. 7% of Revenues)
  • Profit before tax of Rs 18,463 million (Up 26% YoY; Up 39% QoQ)
  • Profit after tax of Rs 14,025 million (Up 18% YoY; Up 46% QoQ)

Commenting on the results, Co-Chairman & MD, G V Prasad, said: "We delivered strong sales growth and witnessed robust margin expansion in Q1FY24 driven by market share gains & new product momentum in our US generics business and superior performance in Russia. We are on track in executing our strategy, delivering growth while continuing to invest in future growth drivers and innovation to create sustainable value."



Result PDF

View Other Company Results


Trading recommendation

Call Date
15 May 2021
Entry Price 5,196.00
Target Price 5,570.00
Stop Loss -
Investment recommendation
In line numbers boosted by gRevlimid, divestitures of brands…
Call Date
11 May 2023
Entry Price 4,550.00
Target Price 5,520.00
12 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Dr Reddys Laboratories Ltd Stocks COMPARISION


Equity Capital: 23,413.00 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 18,676.55 -6,386.02
LAST 3M 37,244.98 6,086.45
LAST 6M 47,342.46 153,492.54
LAST 12M 133,811.11 156,210.35

Dr Reddys Laboratories Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Dr Reddy’s Laboratories Ltd. is an Indian multinational pharmaceutical company. It manufactures and markets a wide range of pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, and biologics. It was incorporated in 1984 with its headquarters in Hyderabad, Telangana. The company’s total income for the quarter ended June 2022 was Rs HYPERLINK "https://economictimes.indiatimes.com/dr-reddys-laboratories-ltd/stocks/companyid-13841.cms" 6,086.80 crore. On 5 August 2022, its market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/drreddyslaboratories/DRL" 69,190 crore.
    The company is listed on the Bombay Stock Exchange with the code 500124 and on the National Stock Exchange with the code DRREDDY. It is also listed on the MCX Stock Exchange.
    Dr Reddy’s Laboratories Ltd. has research and development centres and manufacturing facilities in 66 countries, with an employee strength of more than 24,000. For FY 2021-2022, the company’s profit after tax was Rs 2,182.50 crore, up 11.83% from FY 2020-2021. Its total assets for FY 2021-2022 stood at Rs 29,746.90 crore.
    The company’s shareholding pattern on 30 June 2022 indicated a promoter stake of 26.71%, foreign institutional investor stake of 25.87%, domestic institutional investor stake of 25.19%, and public stake of 21.96%. The promoters have decreased holdings from 26.72% to 26.71% in the June 2022 quarter, while the mutual fund holdings have increased from 14.12% to 14.21%.
    The company’s chairman is Mr K Satish Reddy. The co-chairman and managing director is Mr G V Prasad. The other board members include Mr Leo Puri, Ms Shikha Sharma, Dr Bruce L A Carter, Mr Allan Oberman, Mr Prasad R Menon, Ms Kalpana Morparia, and Mr Sridar Iyengar. The company’s auditors are S R Batliboi & Associates LLP.
    On 5 August 2022, Dr Reddy’s Laboratories Ltd.’s share price on BSE closed at Rs 4154. Its NSE share price closed at Rs 4,156.85. The company’s 52-week high share price was Rs 5,077, and the 52-week low was Rs 3,654.
    As of July 2022, the company’s mutual fund holdings included Franklin India Pension Plan, Aditya Birla SL Equity Hybrid ‘95 Fund, Franklin India Debt Hybrid Fund, and ICICI Prudential Regular Savings Fund with 1.04%, 0.79%, 0.62%, and 0.60% stake, respectively.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

8-2-337 Road No 3, Banjara Hills, Hyderabad, Telangana, 500034

Tel : 91-40-49002900
Email : shares:drreddys.com
Website : http://www.drreddys.com

Bigshare Services Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 500124
Book Closure Date (Month) :
BSE Group : A
ISIN : INE089A01023

FAQ’s on Dr Reddys Laboratories Ltd Shares

You can buy Dr Reddys Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Dr Reddys Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 22, 2023 03:58 PM the closing price of Dr Reddys Laboratories Ltd was ₹ 5,517.05.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 22, 2023 03:58 PM, the market cap of Dr Reddys Laboratories Ltd stood at ₹ 91,889.78.

The latest PE ratio of Dr Reddys Laboratories Ltd as of Sep 22, 2023 03:58 PM is 19.48

The latest PB ratio of Dr Reddys Laboratories Ltd as of Sep 22, 2023 03:58 PM is 0.25

The 52-week high of Dr Reddys Laboratories Ltd is ₹ 5,989.70 while the 52-week low is ₹ 4,089.30

According to analyst recommendations, Dr Reddys Laboratories Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app